Hungary · Delayed Price · Currency is HUF Gedeon Richter Earnings Call Transcripts
Fiscal Year 2025
-
2025 ended with strong revenue and profit growth, led by Women's Health and innovative products, despite FX and tax headwinds. Outlook for 2026 is high single-digit growth, with continued investment in R&D and efficiency, and new product launches expected to drive future gains.
-
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
-
Pharma sales grew 10.7% YoY in H1 2025, with clean EBIT up 15% and Women's Health leading segment growth. FX volatility and inventory write-offs impacted cash flow, but guidance for 10% revenue and EBIT growth remains on track.
-
Q1 2025 saw strong revenue and EBIT growth, record free cash flow, and robust performance in general medicines and biosimilars. Four biosimilar launches are planned within 12 months, and the company maintains a solid cash position to support dividends and R&D.
Fiscal Year 2024
-
Double-digit revenue and profit growth in 2024, with all business units contributing and strong free cash flow. 2025 guidance targets 10% growth despite lower milestone income, with cost controls and new product launches supporting outlook.
-
Revenue and net profit grew strongly year-over-year, driven by broad-based segment growth and successful M&A. Free cash flow and EBIT improved, with new product launches and biosimilar filings supporting future outlook. FX volatility and regulatory uncertainties remain key risks.
-
Recent acquisitions of Mithra and BCI Pharma have enabled full control over the E4 platform and expanded R&D, positioning the business as a leading innovator in women's healthcare. The company aims for HUF 1 billion in sales earlier than planned, focusing on growth, efficiency, and expanding its contraception, fertility, endometriosis, and menopause portfolio.